Clinical Trial Update: Monoclonal Antibody Therapy in Treating Patients With Brain Metastases [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/Phase 2 clinical trial evaluated a monoclonal antibody therapy for brain metastases arising from metastatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Metastases

Drugs mentioned

• Monoclonal antibody therapy (unspecified)

Snippet

Sponsor: Duke University | Conditions: Metastatic Cancer | Phase 1, Phase 2 | Status: COMPLETED